This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CYCC

Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

Cyclacel Pharmaceuticals logo

About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)

Key Stats

Today's Range
$6.37
▼
$6.37
50-Day Range
$6.36
▼
$9.28
52-Week Range
$0.22
▼
$19.87
Volume
N/A
Average Volume
3.54 million shs
Market Capitalization
$14.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapies that target key mechanisms of cell division. Founded in 1996, the company has built a pipeline of experimental small-molecule inhibitors designed to disrupt the activity of cyclin-dependent kinases (CDKs) and other cell cycle regulators. These targeted agents are intended to selectively halt the proliferation of tumor cells while minimizing effects on healthy tissue.

The company’s most advanced programs include fadraciclib (formerly CYC065), an oral CDK2/9 inhibitor in Phase 1/2 studies for advanced solid tumors and hematologic malignancies, and CYC140, a novel allosteric inhibitor of aurora kinases under early clinical evaluation. Cyclacel’s research and development efforts leverage in-house discovery platforms as well as strategic collaborations with academic institutions and contract research organizations. This collaborative model supports rapid translation of laboratory findings into clinical candidates.

Cyclacel is headquartered in Berkeley Heights, New Jersey, with additional research operations in Dundee, Scotland, reflecting its UK-US footprint. Over the years, the company has advanced multiple compounds into human trials, demonstrating its ability to move promising molecules through preclinical stages. Under its experienced management team, Cyclacel continues to explore combination regimens and biomarker-driven approaches to enhance the therapeutic potential of its pipeline agents for patients with hard-to-treat cancers.

AI Generated. May Contain Errors.

Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CYCC Stock News Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
See More Headlines

CYCC Stock Analysis - Frequently Asked Questions

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) released its quarterly earnings results on Wednesday, August, 13th. The biotechnology company reported ($0.98) earnings per share for the quarter, beating analysts' consensus estimates of ($72.00) by $71.02.

Cyclacel Pharmaceuticals's stock reverse split on Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Achieve Life Sciences (ACHV), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX) and Tonix Pharmaceuticals (TNXP).

Company Calendar

Today
11/19/2026
EGM 2026
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Trading Companies & Distributors
Sub-Industry
Trading Companies & Distributors
Current Symbol
NASDAQ:CYCC
CIK
1130166
Employees
14
Year Founded
1992

Profitability

EPS (Trailing Twelve Months)
($839.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.21 million
Net Margins
N/A
Pretax Margin
-54,220.00%
Return on Equity
-723.64%
Return on Assets
-145.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.77
Quick Ratio
5.77

Sales & Book Value

Annual Sales
$40 thousand
Price / Sales
356.44
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($58.87) per share
Price / Book
-0.11

Miscellaneous

Outstanding Shares
2,240,000
Free Float
1,093,000
Market Cap
$14.26 million
Optionable
Optionable
Beta
0.15

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:CYCC) was last updated on 4/8/2026 by MarketBeat.com Staff.
From Our Partners